PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of s., no persons are uired to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 4

Cor	nplete if Known
Application Number	09/735,363
Filing Date	December 12, 2000
First Named Inventor	Phillips et al.
Group Art Unit	1635
Examiner Name	Mary Schmidt
Attorney Docket Number	02811-0181 (42368-250224)

				U.S. PATENT DOCUMENT		
	U.S. Patent Document Kind Code ²			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
Examiner Initials	Cite No. ¹	Number	(if known)		MM-DD-YYYY	Figures Appear
0.2	AA	US 4,983,518		Schaffner, et al.	01/08/1991	
17						
		<u> </u>				

Columns, Lines, Where nt Passages or Figures Appear	T ⁶
	—
	┼
	┼
	┼—
	+

Examiner Signature	\searrow	2	Date Considered	5/	18/0	3

¹Unique citation designation number ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no person are required to re

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

2 Sheet

Con	nplete if Known
Application Number	09/735,363
Filing Date	December 12, 2000
First Named Inventor	Phillips et al.
Group Art Unit	1635
Examiner Name	Mary Schmidt
Attorney Docket Number	02811-0181 (42368-250224)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	ВА	BALLAS et al., "Induction of NK Activity in Murine and Human Cells by CpG Motifs in	
13		Oligodeoxynucleotides and Bacterial DNA," J. Immunol., September 1, 1996, p. 1840-1845, Vol. 157.	
	BB	BATES et al., "Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding," J.	
		Biol. Chem., September 10, 1999, Vol. 274, pp. 26369-26377.	
	ВС	BRAUN et al., "Cytotoxic T Cells Deficient in Both Functional Fas Ligand and Perforin Show Residual	
\		Cytolytic Activity yet Lose Their Capacity to Induce Lethal Acute Graft-Versus-Host Disease," J. Exp.	
		Med., 1996, p. 657-661, Vol. 183.	
	BD	FAMULARO et al., "Fas/Fas Ligand on the Road; An Apoptotic Pathway Common to AIDS,	
		Autoimmunity, Lymphoproliferation and Transplantation," Med. Hypoth., 1999, p. 50-62, Vol. 53.	
 	BE	FILION, M.C. et al., "Inhibition of cell cycle progression and induction of apoptosis in leukemia cells	_
		by Mycobacterium phlei DNA and derived synthetic oligonucleotides." Clinical Cancer Research	
		(November 7-10, 2000), Vol. 6, Supp.; Page 4571S.	
	BF	FILION, M.C. et al., "Mycobacterium phlei cell wall complex directly induces apoptosis in human	
		bladder cancer cells." British Journal of Cancer (January, 1999) 79(2) 229-35.	
 	BG	FILION, M.C., et al., "Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and	
		present in a mycobacterial cell wall complex." Cancer Immunology Immunotherapy (August, 2000),	
		49(6), pgs. 325-34.	
	BH	GRIFFITH, et al., "Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege," Science,	1
		November 17, 1995, Vol. 270, pp. 1189-1192.	
	BI	HOCHHAUSER, D., "Modulation of chemosensitivity through altered expression of cell cycle	
	-	regulatory genes in cancer," Anti-Cancer Drugs, 1997, Vol. 8, pp. 903-910.	
	BJ	KLINMAN et al., "CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete	+
1 /		Interleukin 6, Interleukin 12, and Interferon y," Proc. Natl. Acad. Sci. USA, April, 1996, pp. 2879-	
		2883, Vol. 93.	
	PV	KONDO et al., "Essential Roles of the Fas Ligand in the Development of Hepatitis," Nature Med.,	
11/	BK		
		April, 1997, pp. 409-413, Vol. 3, No. 4.	1

Examiner Signature	7-3	Date Considered	S	128	03
	-/-//-				

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Pane	owork f	Reduction Act of 1995 no persons are requ	ire (P t	respond to a collection of inform	nation unless it contains a valid OMB control number
	Olider the rape	- WOIK	E.	57	Con	nplete if Known
Substitute 1	for Form 1449/A/PTO		RADEMARKO	X	Application Number	09/735,363
			ADEMAND	F	iling Date	December 12, 2000
	INFORMAT	101	N DISCLOSURE	F	irst Named Inventor	Phillips et al.
	STATEMEN	I TI	BY APPLICANT	10	Froup Art Unit	1635
	•		neets as necessary	E	xaminer Name	Mary Schmidt
Sheet	3	of	4	P	Attorney Docket Number	02811-0181 (42368-250224)
CHOCK	•	,				

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Éxaminer Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CA	LIPFORD et al., "CpG-Containing Synthetic Oligonucleotides Promote B and Cytotoxic T Cell	
\bigcap_{α}		Responses to Protein Antigen: A New Class of Vaccine Adjuvants," Eur. J. Immunol., 1997, pp.	
74	Y 1	2340-2344, Vol.27.	
00	СВ	MORASSUTTI, et al., "Correlation between cytotoxic effect and binding to nuclear proteins of	
1		oligomeric d(GT)n sequences in human cancer CCRF-CEM cell line," Minerva Biotec, June, 1995,	
		pp. 176-181.	
	cc	MORASSUTTI, et al., "Effect of Oligomer Length and Base Substitutions On The Cytotoxic Activity	
\		and Specific Nucelar Protein Recognition of GTn Oligonucleotides in the Human Leukemic CCRF-	
		CEM Cell Line," Nucleosides and Nucleotides, 18(6&7), pp. 1711-1716 (1999).	
 	CD	NAGATA, S., "Fas Ligand-Induced Apoptosis," Ann. Rev. Genet., 1999, pp. 29-55, Vol. 33.	
	CE	NISHIOKA et al., "An Augmentation of Fas (CD95/APO-1) Antigen Induced by Radiation: Flow	
		Cytometry Analysis of Lymphoma and Leukemia Cell Lines," Int. J. Mol. Med., 1999, pp. 275-278,	
		Vol. 3.	
	CF	O'CONNELL, et al., "The Fas Counterattack: Fas-Mediated T Cell Killing by Colon Cancer Cells	
		Expressing Fas Ligand," J. Exp. Med., September, 1996, pp. 1075-1082, Vol. 184.	
	CG	OWEN-SCHAUB et al., "Fas and Fas Ligand Interactions in Malignant Disease (Review)," Int. J.	
		Oncol., 2000, pp. 5-12, Vol. 17.	
	СН	Promega Catalog 1993/94, Revolutions in Science, cover and pp. 90-91.	
-	CI	READER, S., et al., "Identification of non-antisense phosphodiester oligonucleotides that induce cell	
		cycle arrest and apoptosis in cancer cells." Clinical Cancer Research (November 7-10, 2000), Vol.	
		6, Supp.; Page 4571S.	
 	CJ	SABELKO-DOWNES et al., "The Role of Fas Ligand in vivo as a Cause and Regulator of	
		Pathogenesis," Curr. Opin. Immunol., June, 2000, pp. 330-335, Vol. 12.	
	/CK	SCAGGIANTE et al., "Human Cancer Cell Lines Growth Inhibition by GT _n Oligodeoxyribonucleotides	
	/	Recognizing Single-Stranded DNA-Binding Proteins," Eur. J. Biochem., March 1, 1998, pp. 207-215,	
		Vol. 252.	
			

Examiner Date S/28/03		\		 T	1		
Signature	Examiner Signature	13	~	Date Considered	5,	128	03

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1982, no persons are recoved to respond to a collection of information unless it contains a valid OMB control number

OTHER INCORMATION MON DATENT LITERATURE DOCUMENTS

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

4

Sheet 4 of

Cor	nplete if Known
Application Number	09/879,668
Filing Date	June 12, 2001
First Named Inventor	Phillips et al.
Group Art Unit	1632
Examiner Name	Not yet assigned
Attorney Docket Number	02811-0181 (42368-250224)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
0.2	DA	SHEARD et al., "UP-Regulation of FAS (CD95) in Human p53 ^{wild-type} Cancer Cells Treated With	
177		Ionizing Radiation," Int. J. Cancer, 27 November, 1997, pp. 757-762, Vol. 73.	
U	DB	VLASSOV et al., "Transport of Oligonucleotides across Natural and Model Membranes," Biochem.	
		Biophys. Acta., 1994, pp. 95-108, Vol. 1197.	
	DC	WAGNER, R., "Gene Inhibition Using Antisense Oligodeoxynucleotides," Nature, 1994, pp. 333-335,	
		Vol. 372.	
	DD	WANG et al., "Unmethylated CpG Motifs Protect Murine B Lymphocytes Against Fas-Mediated	
		Apoptosis," Cellular Immunol., 1997, pp. 162-167, Vol. 180.	
	DE	WYLLIE et al., "Cell Death: The Significance of Apoptosis," Int. Rev. Cytol., 1980, pp. 251-306, Vol.	
		68.	
	DF	WYLLIE A., "Glucocorticoid-Induced Thymocyte Apoptosis is Associated with Endogenous	
		Endonuclease Activation," Nature, 1980, pp. 555-556, Vol. 284.	
- //	DG	YOONG et al., "Fas/Fas Ligand Interaction in Human Colorectal Hepatic Metastases," Am. J. Pathol.,	
V		March, 1999, pp. 693-703, Vol. 154.	

Examiner Signature

Date Considered

5/

¹Unique citation designation humber. ²Applicant is to place a check mark here if English language translation is attached.